Gilead Sciences, Inc. (NASDAQ:GILD) EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total value of $1,122,300.00. Following the transaction, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Gilead Sciences, Inc. (NASDAQ GILD) traded down $1.15 during trading hours on Friday, reaching $73.81. The company had a trading volume of 7,376,747 shares, compared to its average volume of 8,814,002. The stock has a market cap of $96.47 billion, a PE ratio of 7.70 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter last year, the business posted $2.75 EPS. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. equities research analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is currently 23.69%.

TRADEMARK VIOLATION NOTICE: “Gregg H. Alton Sells 15,000 Shares of Gilead Sciences, Inc. (GILD) Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/03/gregg-h-alton-sells-15000-shares-of-gilead-sciences-inc-gild-stock.html.

Several hedge funds have recently made changes to their positions in the business. Keel Point LLC grew its stake in shares of Gilead Sciences by 0.4% in the 1st quarter. Keel Point LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $211,000 after purchasing an additional 11 shares during the last quarter. Paradigm Financial Advisors LLC grew its stake in shares of Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 26 shares during the last quarter. West Oak Capital LLC grew its stake in shares of Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock valued at $330,000 after purchasing an additional 32 shares during the last quarter. First Heartland Consultants Inc. grew its stake in shares of Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock valued at $632,000 after purchasing an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC grew its stake in shares of Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock valued at $691,000 after purchasing an additional 41 shares during the last quarter. Institutional investors own 74.28% of the company’s stock.

GILD has been the subject of a number of research analyst reports. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Redburn Partners initiated coverage on Gilead Sciences in a report on Wednesday, July 26th. They set a “buy” rating for the company. Zacks Investment Research upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a report on Monday, July 17th. Deutsche Bank AG reiterated a “buy” rating and set a $81.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, BidaskClub upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences has a consensus rating of “Buy” and an average target price of $85.68.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.